Skip to main content
Equibles
SYRE logo

SYRE · Spyre Therapeutics, Inc.

Track SYRE — free Ask ALVIS about SYRE
$94.34 -5.71 (-5.70%)
Going-concern doubt — flagged May 5, 2026

Substantial doubt about the company's ability to continue as a going concern.

“We will need to raise additional capital to continue to fund our operations in the future. If we are unable to raise additional capital when needed, we will not be able to continue as a going concern.”
View the 10-Q filed May 5, 2026
Market Cap
$8.69B
Shares
86.84M

Price & Indicators

Indicators
Price
Panels
Event markers
20d MA 50d MA 200d MA Earnings Filing Insider Congress Investor day
Close$100.04 Open$102.50 Day$98.87–105.00 52W$14.51–105.09 Avg vol 30d1.6M Short int12.5M · 14.4% float · 9.0d Short vol70% Last earningsFeb 24, 2020 DataJan 2020–Jul 2026 Filing10-Q · May 5

Up next

FQ3-26 quarter ends
~Sep 30, 2026 Est
Latest filing: 10-Q
filed May 5, 2026

Equibles Rating

blended score · not investment advice
Overall
Buy
SellHoldBuy
Technical Buy Momentum Very Strong Sentiment Bullish Fundamentals Strong Quant / Vol Very High
Market backdrop VIX 18.7 · elevated Equity put/call 0.66
Technical
price trend
Buy
50 / 200-day cross No cross
Price vs 200-day avg +99%
above
Price vs 50-day avg +18%
above
RSI (14) 58
neutral
MACD trend Negative
52-week position 94%
near high
Volume (OBV) Confirms
volume backs price
Momentum
relative strength
Very Strong
1-month return +13%
trailing
6-month return +213%
trailing
YTD return +205%
this year
Relative strength +206%
vs S&P · 6-mo
Sentiment
smart money
Bullish
Trend (MA cross) No cross
50d $85 › 200d $50 — 50d above 200d
Institutional flow Accumulating
23 of 198 funds reported for Jun 30 · net +31.2K sh shares · +5 new
Insider flow Distributing
Net -$416.7M over 90 days · 100% sells
Short interest Falling
14.40% of float · ▼ -8.3% MoM · 9.0 days cover
Volume signal Normal
Volume near normal
Institution breadth Multi-yr high
198 holders — near 3-yr high, broad support
Squeeze score 83
high risk · 0–100
Fundamentals
Strong
EPS growth +155%
Y/Y
Free cash flow $-169.3M
Balance sheet $85.7M
net cash
Quant / Vol
risk profile
Very High
Volatility 70%
annualized · 1-yr
Max drawdown −17%
past year
ATR 6.0%
of price · 14-day

Blended from price, momentum, positioning, fundamentals & volatility · daily-close · not investment advice. Market backdrop is context, not part of the score.

Technicals

trend & momentum for long-term holders Buy
1 · 3 · 3
50 / 200-day cross
No cross Neutral
Price vs 200-day avg
+99% Bullish
Price vs 50-day avg
+18% Bullish
RSI (14)
58 Neutral
MACD trend
Negative Bearish
52-week position
94% Bullish
Volume (OBV)
Confirms Neutral
Market signals — smart money & positioning
Bullish · 3 of 6
Trend (MA cross) No cross
50d $85 › 200d $50 — 50d above 200d
Institutional flow Accumulating
23 of 198 funds reported for Jun 30 · net +31.2K sh shares · +5 new
Insider flow Distributing
Net -$416.7M over 90 days · 100% sells
Short interest Falling
14.40% of float · ▼ -8.3% MoM · 9.0 days cover
Volume signal Normal
Volume near normal
Institution breadth Multi-yr high
198 holders — near 3-yr high, broad support
Price context
position in its 52-week range
52-wk low $15 Now $100 · 94% 52-wk high $105
vs 200-day avg +99% vs 50-day avg +18%

Illustrative technical + ownership context — a signal mix, not investment advice.

Key metrics

the company's own KPIs, from its earnings releases, calls, and filings
Metric Latest Period YoY
Cash Position $756.5M Fourth Quarter 2025 —
Gross proceeds from public offering of common stock $316.2M October 2025 —

Figures exactly as the company stated them · click a metric with a to chart its history · period links open the stating document · "call" marks figures stated on the earnings call, "filing" figures stated in the 10-K/10-Q · YoY needs the prior-year figure on file

Versus peers

Biotechnology — same industry group
Open screener →
Company Mkt cap YTD Rev growth Y/Y P/E Short % shares
SYRE
Spyre Therapeutics, Inc.
this stock
$8.69B +205.4% — — 14.4%
ONC
BeOne Medicines Ltd.
 $471.01B +7.3% +22179.2% 958.5 0.1%
VRTX
Vertex Pharmaceuticals Inc / Ma
 $121.57B +5.7% +46.2% 28.4 2.0%
REGN
Regeneron Pharmaceuticals, Inc.
 $69.95B -13.5% +20.8% 16.3 3.3%
ARGX
Argenx SE
 $55.61B +5.7% — — 2.5%

Peers by industry group · P/E from as-reported trailing EPS · short % is of shares outstanding

At a glance

key data from every section
Ownership
Institutional Holders Accumulating
Holders
201
% held
94.9%
Reported
23 of 198
Top holder
FMR LLC
Held Float
View
Held by Funds
Fund positions
242
View
Short & Settlement
Short Interest Falling
Shares short
12.5M
Days to cover
9.0d
Change
-1.1M sh
View
Short Volume
Short vol %
70%
As of
Jul 27, 2026
Short Total
View
Fails to Deliver
FTD shares
6.6K
Value
$595.1K
As of
Jun 30, 2026
View
Off-Exchange
Off-exchange %
48.0%
Week of
May 4, 2026
Off-exch Lit
View
Smart Money
Insider Trades Net selling
Net (90d)
-$416.7M
Buyers / Sellers
0 / 5
Buyers Sellers
View
Financials
Financials
Revenue (FY)
$0
Net income (FY)
$-155.2M
EPS diluted
$13.76
View
Filings
SEC Filings
Latest
Investor Event Transcript
Filed
Jun 30, 2026
This year
14
View
Proposed Sales
Value
$4.0M
Shares
45.0K
Filed
Jul 1, 2026
View
Exempt Offerings
Offering
$180.0M
Filed
Dec 27, 2023
View
Earnings & Events
Earnings Calls
Last call
Jun 8, 2026
View

Performance

5D 20D 120D MTD YTD
SYRE -0.2% +12.8% +212.8% +12.7% +205.4%
SPY -0.6% +0.7% +6.8% -1.0% +8.4%
vs SPY +0.4% +12.2% +206.0% +13.7% +197.0%
Key facts CIK 1636282 CUSIP 00773J202 13F (30d) 22 filings 22 filers Visit website Investor relations

Report a Problem

Category
Description
Email (optional, for follow-up)